New FDA Approvals

These drugs have received final approval from the U.S. Food and Drug Administration (FDA):

- Dementia agent Exelon (rivastigmine tartrate) by Novartis Pharmaceuticals. Exelon is a reversible cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. Exelon is dosed twice daily and is available in 1.5, 3.0, 4.5, and 6.0 mg capsules.

- Selective H1-receptor antagonist Optivar (azelastine hydrochloride ophthalmic solution) 0.05% by Muro Pharmaceutical Inc. Optivar has received FDA approval for the treatment of itching of the eye associated with allergic conjunctivitis. It is administered topically to the eyes twice daily.